Scientists create vaccine against dangerous designer opioids

Scientists create vaccine against dangerous designer opioids

6:53 AM, 22nd February 2016
Scientists create vaccine against dangerous designer opioids
Key authors from The Scripps Research Institute (Left to right) research associate Atsushi Kimishima, professor Kim Janda and graduate student Paul Bremer.

LA JOLLA, US: With use of synthetic opioid “designer drugs” on the rise, scientists from The Scripps Research Institute (TSRI) have a new strategy to curb addiction and even prevent fatal overdoses.

This study is published in the journal Angewandte Chemie, the scientists report successful preclinical tests of a vaccine that prevents the synthetic opioid fentanyl—which some drug dealers now use as a mix-in or substitute for heroin—from reaching the brain.

“We want to stay one step ahead of these clandestine laboratories making illegal opioids for black market demand,” said Kim Janda, the Ely Callaway Jr prof of chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. “The importance of this new vaccine is that it can block the toxic effects of this drug, a first in the field.”

The need for treatments

The new vaccine targets an opioid called fentanyl, a painkiller 50 to 500 times more potent than morphine. Over the years—to skirt US Drug Enforcement Administration detection—many illicit laboratories have tweaked fentanyl’s molecular structure, selling fentanyl variants under names such as “China white” and acetyl fentanyl, the latter of which was responsible for a cluster of deaths recently in Rhode Island and Pennsylvania.

With so many variants on the market, users have no way of knowing the strength of the drugs they are using, which can lead to fatal overdoses. The US centres for disease control and prevention reported a 200-percent increase in overdose deaths involving opioids from 2000 to 2014, citing the availability of fentanyl and fentanyl variants as a major contributor.

While there are treatments such as naloxone for opioid overdose or methadone for addiction, Janda noted that many people still relapse. “These treatments are working for some people, but there is clearly a gap that needs attention,” he said.

A potential vaccine

Janda and his colleagues tested the vaccine in mouse models of fentanyl addiction and overdose. Mice were given three vaccinations, each two weeks apart—like a series of booster shots. By studying antibodies in the blood, the researchers saw that the immune system was successfully neutralizing fentanyl for months after the last injection. In further tests, the researchers observed that vaccinated mice given fentanyl did not demonstrate “high” behaviour (such as ignoring discomfort).

In fact, a 30-fold greater-than-normal dose of fentanyl was necessary for the drug to activate neural circuits in vaccinated mice. Remarkably, antibodies generated by the vaccine protected against overdose, neutralizing lethal levels of fentanyl.

“To the best of our knowledge, our active vaccine is the first to ablate lethal doses of any drug of abuse,” said Atsushi Kimishima, TSRI research associate, co-first author of the new study with TSRI graduate student Paul Bremer.

“This surprised us the most,” said Bremer.

Importantly, the potential vaccine protects against virtually all fentanyl derivatives and does not cross-react with other drug classes, such as oxycodone. This means those vaccinated would still have painkiller options in medical situations.

The researchers said the next step in this research is to design an even more potent vaccine, perhaps a combined anti-fentanyl and heroin vaccine. “Since heroin is often cut with fentanyl derivatives, a combination vaccine targeting both opioids would be worth investigating,” said Bremer.

This research was supported by the National Institutes of Health’s National Institute on Drug Addiction.

© The Scripps Research Institute News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Perstorp signs MoU at Make in India with MIDC

MALMO, SWEDEN: Perstorp Group said that it has signed a memorandum of understanding (MoU) with Maharashtra Industrial Development Corporation (MIDC), ...

Read more
Fluor bags BASF’s alcohol, plasticizers facility revamp contract

IRVING, US: Fluor Corporation said that it has been awarded an engineering, procurement and construction management (EPCM) contract from BASF, for the ...

Read more
Clariant to expand colour, additive masterbatches production

MUTTENZ, SWITZERLAND: Clariant AG said that it plans to invest more than CHF 7.5 million in specialized equipment and facilities to expand the capabil ...

Read more
Momentive to expand silane capacity in Germany

WATERFORD, US: Momentive Performance Materials Inc said that it will invest approximately $30 million to expand its NXT (trade mark of the company) si ...

Read more
Thomas Swan, Plessey, DelStar to develop graphene applications

CONSETT, UK: Thomas Swan & Company Ltd said that it has been awarded an additional Innovate UK funding for two new collaborative projects in a pro ...

Read more
Asahi Glass develops AMOLEAyd, a new refrigerant grade

TOKYO, JAPAN: Asahi Glass Company Ltd (AGC) said that it has successfully developed AMOLEAyd, a new refrigerant grade for AGC’s AMOLEA brand lin ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X